Contrasting Bioxytran (OTCMKTS:BIXT) & uniQure (NASDAQ:QURE)

Bioxytran (OTCMKTS:BIXT) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Insider & Institutional Ownership

78.8% of uniQure shares are owned by institutional investors. 70.0% of Bioxytran shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Bioxytran and uniQure”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioxytran	N/A	N/A	-$2.12 million	($0.02)	-1.52
uniQure	$16.10 million	105.15	-$198.97 million	($3.48)	-7.71

Bioxytran has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Bioxytran, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bioxytran and uniQure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioxytran	N/A	N/A	-737.48%
uniQure	-1,154.42%	-145.81%	-27.15%

Analyst Ratings

This is a breakdown of recent recommendations for Bioxytran and uniQure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioxytran	0	0	0	0	0.00
uniQure	1	6	10	0	2.53

uniQure has a consensus price target of $42.83, indicating a potential upside of 59.57%. Given uniQure’s stronger consensus rating and higher possible upside, analysts plainly believe uniQure is more favorable than Bioxytran.

Volatility & Risk

Bioxytran has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Summary

Bioxytran beats uniQure on 7 of the 13 factors compared between the two stocks.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.